Related Experiment Video

Updated: Aug 14, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.4K

Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and

Caroline J Coats1, Martin S Maron2, Theodore P Abraham3

  • 1School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.

JACC. Heart Failure
|November 30, 2023
PubMed

Insights

Obstructive hypertrophic cardiomyopathy (oHCM) patients face quality of life issues despite current treatments. The SEQUOIA-HCM trial investigates aficamten to improve exercise capacity and symptoms in oHCM.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Obstructive hypertrophic cardiomyopathy (oHCM) increases risks of serious cardiac events.
  • Despite contemporary management, oHCM patients experience reduced quality of life and persistent symptoms.

Purpose of the Study:

  • To evaluate the efficacy of aficamten in treating obstructive hypertrophic cardiomyopathy.
  • To assess the impact of aficamten on functional capacity and symptoms in oHCM patients.

Main Methods:

  • The SEQUOIA-HCM trial is a Phase 3, randomized, placebo-controlled study.
  • Enrolled 282 ethnically diverse patients with oHCM receiving standard-of-care.
  • Assessed aficamten versus placebo over 24 weeks for functional capacity and symptoms.

Main Results:

  • Baseline characteristics represent a diverse oHCM population with significant symptom burden.
  • The trial is fully enrolled, with data collection ongoing.

Conclusions:

  • The SEQUOIA-HCM trial design provides a model for future oHCM therapy evaluations.
  • Aficamten is being investigated as a potential therapy to alleviate oHCM burden.

Keywords:
aficamtendrug therapyobstructive hypertrophic cardiomyopathyrandomized controlled trial

More Related Videos

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease00:07

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

9.7K
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.5K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...